$599

CAROLINA CVOT Neutral; No Impact to OAD Market

BI/Lilly announced that the CAROLINA CVOT met the primary endpoint of non-inferiority on 3P-MACE vs. glimepiride. Full results from the study are scheduled to be presented on June 10 at the ADA conference. Below, FENIX provides thoughts on CAROLINA and how OAD market dynamics are unlikely to be affected, continuing the slow decline of SU volume share.

This content is for Read Less members only.
Register
Already a member? Log in here